CDC updates MenB-4C vaccine dosing recommendations to align with new FDA label

The Centers for Disease Control and Prevention (CDC) has issued updated recommendations for the dosing interval and schedule of the Bexsero MenB-4C vaccine. This change aligns the public health guidance with a new FDA-approved label for the vaccine. The specific study type, population size, and clinical data supporting this schedule adjustment were not reported in the provided information.

No comparative data against a previous schedule or other vaccines was provided. The main results, including immunogenicity or efficacy outcomes, effect sizes, and statistical measures, were not reported. Similarly, no information on safety, tolerability, or adverse event profiles related to the updated schedule was available.

Key limitations include the absence of reported primary evidence, such as the study design or population characteristics that informed this recommendation. The practice relevance is that clinicians in the United States should be aware of this official update to the vaccine's administration schedule. Implementation should be based on the full CDC guidance and the new FDA label, as the underlying clinical evidence details remain unspecified.